tuftsin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-26 and is reviewed periodically as new material appears.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analog of the tetrapeptide tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Reported consistently across pharmacopoeial descriptions |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| Solubility | Freely soluble in water | Aqueous buffers; poor in nonpolar solvents |
| Typical storage temperature | -20 degrees Celsius | Lyophilized powder; protect from moisture |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
==== Economic reform ==== Libya's economy witnessed increasing privatization; although rejecting the socialist policies of nationalized industry advocated in The Green Book, government figures asserted that they were forging "people's socialism" rather than capitalism. Gaddafi welcomed these reforms, calling for wide-scale privatization in a March 2003 speech; he promised that Libya would join the World Trade Organization. These reforms encouraged private investment in Libya's economy. By 2004, there was US$40 billion of direct foreign investment in Libya, a six-fold rise over 2003. Sectors of Libya's population reacted against these reforms with public demonstrations, and in March 2006, revolutionary hard-liners took control of the GPC cabinet; although scaling back the pace of the changes, they did not halt them. In 2010, plans were announced that would have seen half the Libyan economy privatized over the next decade, these plans appear to have been soon abandoned however, as the companies that the government stated they were going to float on the stock market, among them the National Commercial Bank and the Libyan Iron and Steel Company were never floated and remained 100% state-owned. Many socialist policies remained however, with subsidiaries of logistics company HB Group being nationalized in 2007. Agriculture remained largely untouched by the reforms, with farms remaining cooperatives, the Agricultural Bank of Libya remaining wholly state-owned and state interventionist policies and price controls remaining.
== Business activities == MacKinnon is co-inventor with his friend and scientific collaborator, neurobiologist Bruce Bean of Harvard Medical School, of a dietary supplement for treating and preventing muscle cramps; they tested it in clinical trials and are co-founders a company to commercialize their invention, Flex Pharma. Christoph Westphal and Jennifer Cermak were co-founders as well. The company undertook drug development of a formulation of supplement as a drug candidate for neuromuscular disorders like ALS, and raised a $40 million Series A round. The company had an $86 million initial public offering in 2015. In 2016, the company launched "HotShot" as a dietary supplement for endurance athletes. In June 2018 the company halted clinical development of the drug candidate due to tolerability issues, cut its workforce, and said it was considering its strategy. In July 2018 MacKinnon resigned from the board of directors.
==== Indolethylamine N-methyltransferase (INMT) ==== Before techniques of molecular biology were used to localize indolethylamine N-methyltransferase (INMT), characterization and localization went on a par: samples of the biological material where INMT is hypothesized to be active are subject to enzyme assay. Those enzyme assays are performed either with a radiolabeled methyl donor like (14C-CH3)SAM to which known amounts of unlabeled substrates like tryptamine are added or with addition of a radiolabeled substrate like (14C)NMT to demonstrate in vivo formation. As qualitative determination of the radioactively tagged product of the enzymatic reaction is sufficient to characterize INMT existence and activity (or lack of), analytical methods used in INMT assays are not required to be as sensitive as those needed to directly detect and quantify the minute amounts of endogenously formed DMT. The essentially qualitative method thin layer chromatography (TLC) was thus used in a vast majority of studies. Also, robust evidence that INMT can catalyze transmethylation of tryptamine into NMT and DMT could be provided with reverse isotope dilution analysis coupled to mass spectrometry for rabbit and human lung during the early 1970s. Selectivity rather than sensitivity proved to be a challenge for some TLC methods with the discovery in 1974-1975 that incubating rat blood cells or brain tissue with (14C-CH3)SAM and NMT as a substrate mostly yields tetrahydro-β-carboline derivatives, and negligible amounts of DMT in brain tissue.
Sources: en.wikipedia.org
== Medical uses == Mineralocorticoid receptor antagonists are diuretic drugs that work primarily on the kidneys. They decrease sodium reabsorption, which leads to increased water excretion by the kidneys. By regulating water excretion, mineralocorticoid receptor antagonists lower blood pressure and reduce fluid around the heart which can be very beneficial in some cardiovascular conditions. Mineralocorticoid receptor antagonists have been used for many clinical conditions in the cardiovascular system. It has proven beneficial for diseases like primary aldosteronism, primary and resistant hypertension, heart failure and chronic kidney disease. They are often used with other medications, such as ACE inhibitors or beta blockers.
=== February === 1 February Mike Behrens, lawyer and judge, King's Counsel (since 1999), District Court judge (2004–2011) (born 1941). Dame Iritana Tāwhiwhirangi, Māori language advocate (born 1929). 2 February – Peter Babich, Hall of Fame viticulturist and businessman (born 1932). 5 February – Brian Turner, field hockey player (national team), poet and environmental campaigner, Commonwealth Poetry Prize (1999), Poet Laureate (2003–2005) (born 1944). 6 February – Jim Cole, volcanologist (University of Canterbury), Fellow of the Royal Society of New Zealand (since 2004) (born 1941). 7 February – Ian Barton, forester, heritage advocate (Queen's Redoubt Trust), and local-body politician, Franklin District Councillor (1998–2004) (born 1937). 10 February Lynne Giddings, nursing and women's studies academic (Auckland University of Technology, University of Auckland) (born 1945). Toni Huata, Māori musician (born 1969). Rod McElrea, racing driver, national beach racing champion (1971), OSCA champion (1983) (born 1941). 12 February – Theo Janssen, sculptor, stained-glass artist and painter (born 1934). 13 February – Joe Pope, business executive (Petrocorp, ENZA) and rugby administrator, chair of Hurricanes franchise (1999–2003) and Wellington Rugby Football Union (2003–2009) (born 1941). 15 February David Ellison, Māori leader (Kāti Huirapa), veterans' welfare and children's health advocate (born 1936). David Parsons, musician, composer and ethnomusicologist (born 1944). 17 February – David Saunders, lawyer and judge, District Court judge (1993–2020) (born c. 1951).
=== 1880s === 1880: Self-taught German chemist Agnes Pockels began investigating surface tension, becoming a pioneering figure in the field of surface science. The measurement equipment she developed provided the basic foundation for modern quantitative analyses of surface films. 1880: Norwegian zoologist and malacologist Birgitte Esmark's publication on mollusks becomes the first time in Norway that a woman had a scientific work published. 1881: Italian scientists Evangelina Bottero and Carolina Magistrelli became the first women to achieve doctoral degrees in science in unified Italy. 1883: American ethnologist Erminnie A. Smith, the first female field ethnographer, published her collection of Iroquois legends Myths of the Iroquois. 1884: English zoologist Alice Johnson's paper on newt embryos became the first paper authored by a woman to appear in the Proceedings of the Royal Society. 1885: British naturalist Marian Farquharson became the first female Fellow of the Royal Microscopical Society. 1886: American botanist Emily Lovira Gregory became the first female member of the American Society of Naturalists. 1887: Rachel Lloyd became the first American woman to receive a PhD in chemistry, completing her research at the Swiss University of Zurich. 1888: Russian scientist Sofia Kovalevskaya discovered the Kovalevskaya top, one of a brief list of known rigid body motion examples that are tractable by manipulating equations by hand. 1888: Scottish astronomer Williamina Fleming discovered the Horsehead Nebula on a telescope-photogrammetry plate.
Sources: en.wikipedia.org
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.
The first four residues of Selank reproduce the tuftsin sequence Thr-Lys-Pro-Arg. A Pro-Gly-Pro extension at the C-terminus was added to slow enzymatic breakdown and extend residence time.
It holds marketing authorization in Russia, where nasal drop formulations are sold. No equivalent approval exists in the European Union, the United States, or most other countries.
Sealed, desiccated storage at -20 °C or colder is the standard recommendation for research-grade material. Vials should reach room temperature before they are opened, which limits condensation. Repeated temperature cycling is discouraged.